High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone

British Journal of Haematology

Volumn 106, Issue 3, 1999, Pages 627-633

  Xu, Dawei ^a   Areström, Irene ^a   Virtala, Robert ^a   Pisa, Pavel ^a   Peterson, Curt ^b   Gruber, Astrid ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

AML; Drug resistance; Lrp; Mdr1; MRNA levels; Mrp

Indexed keywords

LUNG RESISTANCE PROTEIN; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0032831135     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01611.x     Document Type: Article

References (34)

1. Barrand, M.A., Rhodes, T., Center, M.S. & Twentyman, P.R. (1993) Chemosensitization and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. European Journal of Cancer, 29A, 408-415.
2. Borg, A.G., Burgess, R., Green, L.M., Scheper, R.J. & Liu Yin, J.A. (1998) Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. British Journal of Haematology, 103, 1083-1091.
3. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
4. Cole, S.P.C., Sparks, K.E., Fraser, K., Loe, D.W., Grant, C.E., Wilson, G.M. & Deeley, R.G. (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Research, 54, 5902-5910.
5. Filipits, M., Pohl, G., Stranzl, T., Suchomel, R.W., Scheper, R.J., Jager, U., Geissler, K., Lechner, K. & Pirker, R. (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91, 1508-1513.
6. Filipits, M., Suchomel, R.W., Zöchbauer, S., Brunner, R., Lechner, K. & Pirker, R. (1997) Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clinical Cancer Research, 3, 1419-1425.
7. Futscher, B.W., Abbaszadegan, M.R., Domann, F. & Dalton, W.S. (1994) Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochemical Pharmacology, 47, 1601-1606.
8. Gruber, A., Vitols, S., Norgren, S., Areström, I., Peterson, C., Björkholm, M., Reizenstein, P. & Luthman, H. (1992) Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. British Journal of Cancer, 66, 266-272.
9. Hart, S.M., Ganeshaguru, K., Hoffbrand, A.V., Prentice, H.G. & Mehta, A.B. (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia, 8, 2163-2168.
10. Hart, S.M., Ganeshaguru, K., Jones, D.T., Gordon, M. & Prentice, H.G. (1998) Overexpression of the lung resistance protein LRP may be predictive of poor response to therapy in AML. Blood, 92, (Suppl. 1), 385a.
11. Hart, S.M., Ganeshaguru, K., Scheper, R.J., Prentice, H.G., Hoffbrand, A.V. & Mehta, A.B. (1997) Expression of the human major vault protein LRP in acute myeloid leukemia. Experimental Haematolgy, 25, 1227-1232.
12. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Schroeijers, A.B., Van der Valk, P. & Scheper, R.J. (1996a) Major vault protein LRP-related multidrug resistance. European Journal of Cancer, 32A, 979-984.
13. Izquierdo, M.A., Shoemaker, R.H., Flens, M.J., Scheffer, G.L., Wu, L. & Prather, T.R. (1996b) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. International Journal of Cancer, 65, 230-237.
14. Izquierdo, M.A., Van der Zee, A.G.J., Vermorken, J.B., Van der Valk, P., Beliën, J.A.M., Giaccone, G., Scheffer, G.L., Flens, M.J., Pinedo, H.M., Kenemans, P., Meijer, C.J.L.M., De Vries, E.G.E. & Scheper, R.J. (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. Journal of the National Cancer Institute, 87, 1230-1237.
15. Laurençot, C.M., Scheffer, G.L., Scheper, R.J. & Shoemaker, R.H. (1997) Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. International Journal of Cancer, 72, 1021-1026.
16. Legrand, O., Simonin, G., Zittoun, R. & Marie, J.-P. (1998) Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia, 12, 1367-1374.
17. Leith, C.P., Kopecky, K.J., Chen, I.M., Slovak, M., Head, D.R., Weick, J., Appelbaum, F.R. & Willman, C.L. (1997a) Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP1 and LRP in acute myeloid leukemia in patients less than 65 years old. A Southwest Oncology Group study. Blood, 90, (Suppl. 1), 389a.
18. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997b) Acute myeloid leukemia in the elderly, assessment of multidrug resistance (mdr1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-3329.
19. List, A.F., Kopecky, K.J., Willman, C.L., Spier, C., Dorr, R., Flaherty, L., Hynes, H. & Appelbaum, F. (1998) Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML. A Southwest Oncology Group (SWOG) study. Blood, 92, (Suppl. 1), 312a.
20. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J. & Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464-2469.
21. Liu Yin, J.A., Wheatly, K., Rees, J. & Burnett, A. (1998) Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukemia: results of the U.K. Medical Research Council AML-R trial. Blood, 92, (Suppl. 1), 231a.
22. Lorcio, A., Rappa, G., Flavell, R.A. & Sartorelli, A.C. (1996) Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Research, 56, 5351-5355.
23. Marie, J.-P., Bastie, J.-N., Coloma, F., Suberville, A.-M.F., Delmer, A., Rio, B., Delmas-Marsalet, B., Leroux, G., Casassus, P., Baumelou, E., Catalin, J. & Zittoun, R. (1991) Cyclosporin A as a modifier agent in salvage treatment of acute leukemia (AL). Leukemia, 7, 821-824.
24. Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R.J. & Baccarani, M. (1999) P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. British Journal of Haematology, 194, 328-335.
25. Pirker, R., Stranzl, T., Pohl, G., Heinzl, H., Jäger, U., Geissler, K., Lechner, K. & Filipits, M. (1998) Drug resistance factors in acute myeloid leukemia: a comparative analysis. Blood, 92, (Suppl. 1), 386a.
26. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. & Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal of the National Cancer Institute, 83, 708-712.
27. Raaijmakers, H.G.P., Izquierdo, M.A.I., Lokhorst, H.M., De Leuv, C., Belien, J.A.M., Bloem, A.C., Dekker, A.W., Scheper, R.J. & Sonneveld, P. (1998) Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, 91, 1029-1036.
28. Rome, L., Kedersha, N. & Chugani, D. (1991) Unlocking vaults: organelles in search of a function. Trends in Cell Biology, 1, 47-50.
29. Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer, C.J.L.M., Clevers, H.C. & Scheper, R.J. (1995) The drug resistance-related protein LRP is the human major vault protein. Nature Medicine, 1, 578-582.
30. Scheper, R.J., Broxterman, H.J., Scheffer, G.L., Kaaijk, P., Dalton, W.S., Van Heijningen, T.H.M., Van Kalken, C.K., Slovak, M.L., De Vries, E.G.E., Van der Valk, P., Meijer, C.J.L.M. & Pinedo, H.M. (1993) Overexpression of a 110 kD vesicular protein in non-P-glycoprotein mediated multidrug-resistance. Cancer Research, 53, 1475-1479.
31. Schneider, E., Cowan, K.H., Bader, H., Toomey, S., Schwartz, G.N., Karp, J.E., Burke, P.J. & Kaufmann, S.H. (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85, 186-193.
32. Van den Heuvel-Eibrink, M.M., Van der Holt, B., te-Boekhorst, P.A.W., Pieters, R., Schoester, M., Löwenberg, B. & Sonneveld, P. (1997) Mdr1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology, 99, 76-83.
33. Xu, D., Knaust, E., Pisa, P., Palucka, K., Lundeberg, J., Areström, I., Peterson, C. & Gruber, A. (1996) Levels of mdr1 and mrp mRNA expression in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. British Journal of Haematology, 92, 847-854.
34. Zhou, D.-C., Zittoun, R. & Marie, J.-P. (1995) Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia, 9, 1661-1666.